Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Climb Bio (CLYM) Shares Outstanding (2020 - 2026)

Climb Bio filings provide 7 years of Shares Outstanding readings, the most recent being $47.8 million for Q1 2026.

  • Quarterly Shares Outstanding fell 29.31% to $47.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $47.8 million through Mar 2026, down 29.31% year-over-year, with the annual reading at $47.8 million for FY2025, 28.98% down from the prior year.
  • Shares Outstanding hit $47.8 million in Q1 2026 for Climb Bio, roughly flat from $47.8 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $68.2 million in Q3 2025 and bottomed at $26.2 million in Q1 2022.
  • Average Shares Outstanding over 5 years is $43.6 million, with a median of $27.7 million recorded in 2024.
  • The largest annual shift saw Shares Outstanding skyrocketed 654.38% in 2022 before it dropped 29.31% in 2026.
  • Climb Bio's Shares Outstanding stood at $26.4 million in 2022, then grew by 4.68% to $27.6 million in 2023, then surged by 143.45% to $67.3 million in 2024, then dropped by 28.98% to $47.8 million in 2025, then grew by 0.0% to $47.8 million in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Shares Outstanding are $47.8 million (Q1 2026), $47.8 million (Q4 2025), and $68.2 million (Q3 2025).